Cancer Retains Top Spots In Alliance Deal Volume, Value

 
• By Joseph Haas
  
Cancer assets drove 36% of alliance dealmaking in biopharma in 2024 (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Strategy